Chinese companies are leading the fundraising, accounting for 97 percent of the proceeds raised, the data showed. There are 196 Chinese companies listed on major US exchanges with a combined market value US$1.2 trillion, Bloomberg’s data showed. Among those firms, BeiGene Ltd (百濟神州) and Alibaba are the only two with a second listing in Hong Kong. Pfizer chief executive Albert Bourla on Tuesday said that he expected Glaxo to pursue an IPO in three to four years. However, Glaxo chief strategy officer David Redfern said in an interview at the meeting on Wednesday that an IPO is not the only option.
